Innatus Therapeutics

Innatus Therapeutics is a pre-clinical stage biotechnology company dedicated to developing next-generation small molecule inhibitors of the NLRP3 inflammasome. Spun out from the Icahn School of Medicine at Mount Sinai, the company utilizes proprietary chemical scaffolds to target the innate immune system's inflammatory pathways. Their therapeutic focus encompasses a broad range of high-unmet-need areas, including neurodegenerative diseases like Alzheimer's and Parkinson's, as well as metabolic and fibrotic conditions such as NASH. By selectively modulating NLRP3, Innatus aims to provide potent, brain-penetrant, and safe treatments for chronic inflammatory disorders. The company's leadership combines deep academic research in immunology with experienced drug discovery expertise. Innatus is currently advancing its lead candidates through lead optimization and IND-enabling studies.